Atreya R, Kuhbacher T, Vieth M, Jefremow A, et al. Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial. Inflamm Bowel Dis 2026 May 12:izag046. doi: 10.1093.
PMID: 42118952